Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | DDO | Q99489 | 1/20 | 0.58 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.53 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505966 | 1.00 | DAO (0.58) | DAOBRD4DDOPADI4IL4I1 | |
| SCHEMBL1367711 | 0.85 | DAO (0.61) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL31394 | 0.84 | KDM4E (0.59) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL29364659 | 0.84 | KDM4E (0.59) | DAOBRD4DDOPADI4SMYD3 | |
| Hydrochloric Acid SCHEMBL5027809 | 0.82 | KDM4E (0.58) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL29390425 | 0.82 | DAO (0.58) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL29537 | 0.82 | DAO (0.58) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL16627746 | 0.82 | DAO (0.58) | DAOBRD4DDOPADI4SMYD3 | |
| Fluoride SCHEMBL29664116 | 0.82 | KDM4E (0.58) | DAOBRD4DDOPADI4SMYD3 | |
| SCHEMBL16627751 | 0.82 | DAO (0.58) | DAOBRD4DDOPADI4IL4I1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3510025-B1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-110248934-B | Heteroaryl PAD4 inhibitors | 帕德罗科治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3510025-A1 | HETEROARYL INHIBITORS OF PAD4 | Padlock Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003006443-A2 | 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | DAO 876/4885BRD4 2615/4885DDO 261/4885 |
| US-20210299115-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | DAO 912/4885BRD4 57/4885DDO 388/4885 |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | TERT, POT1, REV1 | DAO 1475/4885BRD4 3384/4885DDO 2914/4885 |
| US-11026937-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | DAO 912/4885BRD4 57/4885DDO 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.